Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 7412345...102030...Last »

U.S. Alzheimer’s deaths jump 54 percent

U.S. deaths from Alzheimer’s disease rose by more than 50 percent from 1999 to 2014 – and rates are expected to continue to rise – reflecting the nation’s aging population and increasing life expectancy, American researchers said.

Read More »

Aerie Rockets as Eye Drug Wows in Key Phase III Study

Shares of Aerie Pharmaceuticals were soaring more than 35 percent after the company announced Phase III data for its combination glaucoma drug, Roclatan, met efficacy endpoints.

Read More »

AstraZeneca asthma shot hits goal

AstraZeneca’s experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study.

Read More »

Celgene’s multiple sclerosis drug succeeds in late-stage trial

Celgene Corp. said its oral drug to treat relapsing multiple sclerosis met the main goal in a second late-stage study.

Read More »

5 Biotechs Releasing Highly Anticipated Data

A look at five biotech companies in the cancer market and their upcoming releases at the 2017 American Society of Clinical Oncology (ASCO).

Read More »

Shire’s Lanadelumab Wows in Phase III Study

Shire’s 2015 bet on Dyax and its experimental drug to treat the rare illness, hereditary angioedema (HAE), is paying off. The company revealed stellar Phase III data for lanadelumab that could transform the way HAE patients are treated.

Read More »

J&J Plans 10 Blockbuster Approvals by 2021

In meeting with industry analysts, J&J indicated it expects to have 10 new products approved between 2017 and 2021 that have blockbuster potential.

Read More »

Safety Concerns Raised for Ionis’ Inotersen

Ionis Pharmaceuticals said its Phase III study of inotersen to treat patients with familial amyloid polyneuropathy (FAP) met primary and secondary endpoints.

Read More »

Migraine drug meets main late-stage studies goal

Patients with episodic and chronic migraine reported fewer debilitating headaches after using Eli Lilly’s experimental drug compared to those on placebo.

Read More »

Durvalumab reduces risk of death from lung cancer

A trial of AstraZeneca’s key immunotherapy drug durvalumab showed it reduced the risk of death from advanced lung cancer.

Read More »

Roche’s star cancer drug stumbles in study

Roche’s Tecentriq immuno-oncology drug failed a late-stage follow-up trial against advanced bladder cancer, the Swiss drugmaker said.

Read More »

AstraZeneca, Pieris strike respiratory drug deal

AstraZeneca boosted its early-stage respiratory drug pipeline by signing a deal with Pieris to develop novel inhaled drugs that could fight asthma in new ways.

Read More »

AstraZeneca Dumps Two Drugs From Pipeline

As AstraZeneca faces declining revenue in 2017 from the loss of patents and the challenge of generic drugs, the company culled two drugs from its pipeline.

Read More »

AstraZeneca’s Lung Cancer Trial Gets Delayed

As AstraZeneca continues to move its operations to new headquarters in Cambridge, England, the company quietly pushed back its timeline for a late-stage lung cancer trial.

Read More »

AbbVie cancer drug fails two late-stage trials

AbbVie Inc. said its experimental cancer drug, veliparib, failed to meet the main goals of two late-stage studies.

Read More »

Gates backs push to wipe out tropical diseases

The Bill and Melinda Gates Foundation, Western countries and drug companies pledged fresh support to wipe out diseases in tropical areas.

Read More »

OncoMed Lung Cancer Med Fails Phase II

Shares of OncoMed Pharmaceuticals were down after the company announced its mid-stage combination lung cancer treatment failed to meet endpoints.

Read More »

Hemophilia drug: positive results with children

Roche’s emicizumab drug for treating hemophilia A showed positive interim results in a phase III study with children with inhibitors to clotting protein factor VIII.

Read More »

OncoMed sinks as cancer drug fails

OncoMed Pharmaceuticals is discontinuing a trial testing its experimental drug demcizumab as an initial therapy for advanced pancreatic cancer.

Read More »

Roche’s Alecensa notches trial win against Pfizer’s Xalkori

Roche’s Alecensa kept people with a specific lung cancer alive longer without their disease progressing than Xalkori as it seeks to move in on Pfizer’s share of early treatment of the disease.

Read More »

Page 1 of 7412345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2017 Focus: Agency Profiles, Manny Awards and more!


Ad Right Bottom

Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.

Main Navigation